Latest News - Pfizer
Top Corporates Hub
Pfizer
Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders
09.04.2026 14:00
NEW YORK, April 09, 2026--Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual 2026 Annual Meeting of Shareholders on Thursday, April 23, 2026, at 9:00 a.m. EDT.
Q4 Earnings Highs And Lows: Pfizer (NYSE:PFE) Vs The Rest Of The Branded Pharmaceuticals Stocks
09.04.2026 11:41
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Pfizer (NYSE:PFE) and its peers.
Is Pfizer (PFE) Offering Value After Its 31% One Year Share Price Jump
09.04.2026 11:08
If you are wondering whether Pfizer at around US$27.47 is a bargain or a value trap, the key is understanding what the current price actually implies about the company. The stock is up 9.1% year to date and 31.0% over the last year, even though it shows a 3.8% decline over the past week and a 2.5% gain over the past month. These moves can change how the market views both its potential and its risks. Recent headlines have focused on Pfizer's shifting pipeline mix, product portfolio updates,...
$1.05 Bn Biopharmaceutical CXO Markets - Global Forecast Report 2026-2032: How Leading Pharmas Such as Pfizer, Roche, Novartis, Sanofi, and AstraZeneca Navigate the Evolving Dynamics
09.04.2026 10:05
The biopharmaceutical CXO market offers opportunities in strategic outsourcing, digital integration, resilient supply chains, and value-driven partnerships amidst evolving regulatory landscapes. Biopharmaceutical CXO Market Biopharmaceutical CXO Market Dublin, April 09, 2026 (GLOBE NEWSWIRE) -- The "Biopharmaceutical CXO Market - Global Forecast 2026-2032" report has been added to ResearchAndMarkets.com's offering. The Biopharmaceutical CXO Market grew from USD 655.12 million in 2025 to USD 706.
My 2 Favorite Mispriced Dividends For Recurring Income
09.04.2026 08:35
Rexford (REXR) and Pfizer (PFE) look undervalued despite market pessimism.
Assessing Novavax (NVAX) Valuation After Renewed Focus On Covid And Malaria Vaccine Deals
08.04.2026 12:09
Novavax (NVAX) is back in focus after fresh attention on its Covid and malaria vaccine portfolio and existing collaborations with partners such as Sanofi, Pfizer, Takeda and Serum Life Sciences, prompting investors to reassess the stock’s recent swings. See our latest analysis for Novavax. The recent spotlight on Covid and malaria vaccines comes after a choppy period for the shares, with a 30 day share price return of a 20.04% decline, a 90 day share price return of a 4.72% gain, and a 1 year...
Pfizer Reshapes Portfolio With Seagen And Metsera As COVID Winds Shift
08.04.2026 05:07
Pfizer (NYSE:PFE) is accelerating its transformation with acquisitions of Seagen and Metsera to expand in oncology and anti obesity treatments. The company is dealing with lower COVID related revenues and the halt of a key COVID vaccine trial while advancing mRNA and Lyme vaccine programs. Pfizer reports a pipeline of more than 100 candidates, alongside cost cutting efforts and balance sheet adjustments during this transition phase. For investors watching large pharma, Pfizer now sits at...
2 Healthcare Stocks for Long-Term Investors and 1 We Ignore
06.04.2026 15:31
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks have collectively shed 1.5%. This performance was similar to the S&P 500’s decline.
Poland, Romania Ordered to Honor Vaccine Deal with Pfizer
04.04.2026 05:04
Pfizer Inc. (NYSE:PFE) is included among the 15 Cheapest Stocks with Highest Dividends. On April 1, Reuters reported that a Belgian court ordered Poland and Romania to take delivery of €1.9B ($2.2B) worth of COVID-19 vaccines made by Pfizer Inc. (NYSE:PFE) and BioNTech. The case has been building for some time. Pfizer brought the lawsuit […]
Trump tariff fallout: Some industries grapple with lingering effects one year later
03.04.2026 07:30
A year after his "liberation day," Trump's trade war has reshaped how companies in industries such as retail and autos are modeling economic and policy risk.
Pfizer Site Closure Puts Cost Focus And R&D Productivity In Spotlight
02.04.2026 17:13
Pfizer is closing its South San Francisco research site as part of a wider expense reduction effort. Staff at the site are being transitioned to remote work instead of relocating to another physical office. The company aims to concentrate investments in areas it sees as offering the strongest long term return potential. For investors watching NYSE:PFE, the closure of a major research hub is a concrete operational move rather than a routine update. Pfizer shares most recently traded at...
Boost Pfizer's Already Hefty 6% Dividend Yield With A Covered Call
02.04.2026 15:37
Pfizer stock offers a beefy dividend yield. This options strategy makes the drugmaker's yield even more appealing.
Pediatric Neuroblastoma Treatment Market Outlook 2026-2030 & 2035 - United Therapeutics Corporation, APEIRON Biologics, Pfizer, Bayer, and Amgen Dominate
02.04.2026 10:13
The market offers opportunities in targeted therapies, increasing CAR T-cell and monoclonal antibody use, personalized medicine, and infrastructure investments Pediatric Neuroblastoma Treatment Market Pediatric Neuroblastoma Treatment Market Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Pediatric Neuroblastoma Treatment Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report provides a detailed analysis of market size, regional shares, competitor strategies, and tre
Pfizer (PFE) Valuation Check After Recent Share Price Rebound And Mixed Growth Outlook
02.04.2026 08:11
Recent Performance Snapshot Pfizer (PFE) has drawn attention after recent share price moves, with the stock closing at $28.55. Investors are weighing this level against its recent returns and the company’s current financial profile. See our latest analysis for Pfizer. Recent trading has been positive, with a 1-day share price return of 1.67% at $28.55 and a 90-day share price return of 14.66%. The 3-year total shareholder return of 17.65% contrasts with a 23.98% total shareholder return over...
Pfizer Pulls Back From South San Francisco
01.04.2026 13:30
The move points to a quieter reset in one of biotech's most watched hubs.
GSK's Partner Shionogi Acquires Pfizer's Stake In ViiV Healthcare For $2.125B
01.04.2026 08:13
https://www.shionogi.com/global/en/news/2026/04/20260401_12.html
Will Pfizer’s Lyme disease gamble pay off or set the space back?
01.04.2026 08:00
As the disease spreads into new regions, the urgency for prevention is growing.
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
30.03.2026 13:00
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Pfizer’s (PFE) Shares Up Since Jim Cramer Said “Pass”
30.03.2026 11:06
Pfizer Inc. (NYSE:PFE) is one of Jim Cramer’s Hottest GLP-1 and Weight Loss Stock Picks. Pfizer Inc. (NYSE:PFE) is one of the largest pharmaceutical companies in the world. It operates in the weight loss drug market by developing a treatment that will be administered only once a month. The shares are up by 6.7% over […]
Pfizer (PFE) – Among the 15 Large Cap Stocks with Highest Dividends
30.03.2026 06:08
Pfizer Inc. (NYSE:PFE) is included among the 15 Large Cap Stocks with Highest Dividends. Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company’s global portfolio includes medicines and vaccines, as well as many of the world’s best-known consumer health care products. Pfizer Inc. (NYSE:PFE) […]